The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.
What is Dulaglutide?
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered as a fusion protein combining a modified GLP-1 analog linked to a human IgG4 Fc domain. This structural design extends its half-life to approximately five days, enabling once-weekly subcutaneous dosing. It mimics the action of endogenous GLP-1, an incretin hormone released from intestinal L-cells in response to food intake, by binding to and activating GLP-1 receptors throughout the body.
The primary mechanism through which dulaglutide produces weight loss is multifactorial. It stimulates glucose-dependent insulin secretion from pancreatic beta cells [1], suppresses inappropriate glucagon secretion from alpha cells, and slows gastric emptying to reduce the rate at which nutrients enter the bloodstream after meals. Critically for weight management, GLP-1 receptor activation in hypothalamic and brainstem centers that regulate appetite leads to reduced hunger signaling and earlier satiety, resulting in reduced caloric intake over time.
Clinical trials have documented meaningful weight reduction across the available dose range. At the lowest approved dose (0.75 mg weekly), average weight loss approximates 1.5 to 2.5 kg over 26 weeks. At the maximum approved dose of 4.5 mg weekly, clinical data show an average body weight reduction of approximately 10.4%, which is clinically meaningful and approaches outcomes seen with other high-efficacy GLP-1 class agents. The AWARD and REWIND trial programs established cardiovascular benefits as well, including reduced risk of major adverse cardiovascular events [2] in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.
Recent research has expanded understanding of dulaglutide's mechanisms beyond glucose and weight. A 2025 study published in Diabetes demonstrated weight-independent therapeutic effects on hepatic steatosis: dulaglutide reduced de novo lipogenesis, decreased lipid droplet stability, attenuated hepatic inflammation, and lowered oxidative stress in liver tissue, independent of body weight changes. These findings suggest a direct hepatoprotective role that may be relevant to metabolic-associated steatotic liver disease (MASLD), though this indication remains under investigation.
Research Supply
Source high-purity Dulaglutide for your research
Dosage Guide
Route: Subcutaneous injection, once weekly; prefilled single-dose pens
Dosing Schedule
| Period | Dose |
|---|---|
| Weeks 1-4 | 0.75 mg (initial dose; type 2 diabetes monotherapy) |
| Weeks 5+ | 1.5 mg (standard maintenance dose) |
| Optional escalation | 3.0 mg at 4-week intervals based on tolerability |
| Maximum dose | 4.5 mg weekly (greatest weight loss effect) |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 0.75 mg | 0.5 mL | Single pen injection |
| 1.5 mg | 0.5 mL | Single pen injection |
| 3.0 mg | 0.5 mL | Single pen injection |
| 4.5 mg | 0.5 mL | Single pen injection |
Administration Tips
- Begin at 0.75 mg once weekly for 4 weeks, then increase to 1.5 mg
- Further increases to 3.0 mg and 4.5 mg may be made at 4-week intervals
- Administer on the same day each week; day of week may be changed if last dose was 3+ days prior
- Can be administered at any time of day, with or without food
- Rotate injection sites: abdomen, thigh, or upper arm
- Dulaglutide is used outside of its FDA-approved type 2 diabetes indication in some research and clinical weight management contexts
Risks & Side Effects
Commonly Reported
Serious Risks
Pancreatitis
Acute pancreatitis has been reported with dulaglutide. Discontinue immediately if suspected and seek urgent medical care.
Hypoglycemia
Risk increases significantly when combined with insulin or sulfonylureas. Monitor blood glucose carefully in combination therapy.
Acute kidney injury
Often secondary to severe gastrointestinal fluid losses. Monitor renal function, particularly during episodes of nausea, vomiting, or diarrhea.
Severe gastrointestinal disease
Ileus and gastroparesis have been reported. Use with caution in patients with pre-existing gastroparesis.
Thyroid C-cell tumors
Observed in rodent studies at all doses tested. Dulaglutide carries a boxed warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to dulaglutide or any component of the formulation
- Pregnancy (weight loss not recommended; GLP-1 receptor agonists should be discontinued at least 2 months before planned conception)
Related Peptides
Experts Covering Dulaglutide
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Dulaglutide has not been approved by the FDA for weight loss as a primary indication; its FDA approval covers glycemic management in type 2 diabetes and cardiovascular risk reduction. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.
Frequently Asked Questions
What is Dulaglutide and how does it work?
How much weight can you lose on Dulaglutide?
What is the Dulaglutide dosage schedule?
What are Dulaglutide side effects?
How does Dulaglutide compare to Semaglutide and Liraglutide?
Is Dulaglutide FDA approved for weight loss?
References
- Wysham C, Blevins T, Arakaki R, et al.. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014. PMID 24879836
- Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID 31189511
- Dungan KM, Povedano ST, Forst T, et al.. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes Obes Metab. 2016. PMID 26362460
Regulatory & Official Sources
- Dulaglutide — Wikipedia
- Trulicity (dulaglutide) prescribing information — National Library of Medicine (DailyMed)